Clinical Trial Update: A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy [Phase 2]

View source ↗

Summary

This document provides an update on Hoffmann-La Roche's Phase 2 study of RO7204239 for facioscapulohumeral muscular dystrophy, currently active but not recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy

Drugs mentioned

• RO7204239

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 2 | Status: ACTIVE_NOT_RECRUITING